RT Journal Article
SR Electronic
T1 Genetic Analysis in Anal and Cervical Cancer: Exploratory Findings About Radioresistance in the ProfiLER Database
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 515
OP 520
DO 10.21873/cgp.20276
VO 18
IS 4
A1 ELISE ROWINSKI
A1 NICOLAS MAGNE
A1 WAFA BOULEFTOUR
A1 PABLO MORENO-ACOSTA
A1 CHRISTELLE DE LA FOURCHADIERE
A1 ISABELLE RAY-COQUARD
A1 QING WANG
A1 JEAN-YVES BLAY
A1 OLIVIER TREDAN
YR 2021
UL http://cgp.iiarjournals.org/content/18/4/515.abstract
AB Background/Aim: This study aimed to describe genomic alterations on squamous cell cervical and anal carcinomas. Materials and Methods: From 2013 to 2019, 3,269 patients were included in the molecular screening ProfiLER trial. Only patients with non-metastatic cervical or anal cancer, and those initially treated with radiotherapy in a curative intent were selected. Genetic analyses were performed by next generation sequencing (NGS). Results: Genomic alterations were observed in most patients: 5 patients out of 15 (33.3%) had at least one mutation on NGS and 4 out of 15 (26.7%) had at least one aberration of the number of copies of genes in the comparative genomic hybridation (CGH) analysis. The most common mutated gene was PIK3CA. Conclusion: All omic approaches must be integrated in the locally advanced cancer setting by new clinical trial design to develop two routes in the treatment strategy: intensification or de-escalation treatment strategy according to omic markers.